Ultragenyx Pharmaceutical has sold two priority review vouchers, bringing in $413 million. The vouchers were each earned through FDA approvals of gene therapies, and both therapies had come to Ultragenyx through earlier business development agreements.
The company said the proceeds put it in a stronger financial position to pursue another deal for a rare disease. The sales effectively convert regulatory milestones into cash that can be used for further pipeline expansion.
With only one source available, there are no conflicting accounts to note. The report focuses on the financial outcome and Ultragenyx's stated intent to keep building through acquisitions or partnerships.